For head and neck cancer patients, HPV‐positive status is associated with immune response mechanisms to PD‐1 blockade, with anti‐PD‐1/PD‐L1 treatment potentially serving as an effective therapeutic strategy by restoring CD8+ T cell function to enhance antitumor immune responses. Here, PDCD1 is linked to head and neck cancer.